|
Iressa Expanded Access Program (EAP) Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Iressa Expanded Access Program (EAP) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Iressa Expanded Access Program (EAP) Clinical research trials and Iressa Expanded Access Program (EAP) healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Iressa Expanded Access Program (EAP). Iressa Expanded Access Program (EAP) Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Iressa Expanded Access Program (EAP) clinical trial. Subjects frequently obtain the most expert healthcare possible for their Iressa Expanded Access Program (EAP) condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Iressa Expanded Access Program (EAP)  Iressa Expanded Access Program (EAP)
Iressa Expanded Access Program (EAP)
For Condition: Carcinoma, Non-Small-Cell Lung,Metastases, Neoplasm
Status: No longer recruiting
Sponsor(s): AstraZeneca ,
Synopsis: To provide single agent ZD1839 to patients with advanced (inoperable stage III or IV) non-small cell lung cancer who have failed standard treatment, or patients who can not receive other systemic anticancer therapy, or patients who are not medically suitable for chemotherapy, or because of either unavailability or ineligibility for other clinical trials with ZD1839 (e.g., poor performance status, lack of geographic proximity).
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Single Group Assignment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria For inclusion in this trial, patients must fulfill all of the following criteria: - previous documented histologically or cytologically confirmed non-small cell lung cancer; - locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV)patients who have received at least one course of standard systemic chemotherapy or radiation therapy or are ineligible for chemotherapy or radiotherapy or are ineligible or not a candidate for enrollment on another ZD1839 trial or who, in the Investigator's opinion, are not medically suitable for chemotherapy. - age 18 years or older; - written informed consent to participate in the trial. Exclusion Criteria Any of the following will exclude a patient from entering the trial: - receiving concurrent radiotherapy, chemotherapy, or other systemic anti-cancer medication or any other investigational agent. * Non-cytotoxic or hormonal therapies for the adjuvant treatment of cancer or for previously treated cancers may be allowed per AstraZeneca permission; - patients eligible for or previously enrolled on a ZD1839 blinded clinical trial protocol. Patients eligible for or previously enrolled on an open-label or unblinded ZD1839 clinical trial may be considered for acceptance into the Expanded Access Program with AstraZeneca permission; - having other active malignancies; - incomplete healing from previous oncologic or other major surgery; - evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial; - pregnancy or breast feeding (women of child-bearing potential).
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 1839IL/0050;
Study Start Date:
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034879
Other Carcinoma, Non-Small-Cell Lung Studies:
1. A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 Given Orally Once Daily in Subjects with Metastatic Prostate Cancer
2. Evaluation of Bay 59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
3. Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer
4. Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma
5. An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.
Related Studies:
Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Nebraska Clinical Trials
Other Lincoln Clinical Trials
Iressa Expanded Access Program (EAP)
|
|
|
|
|
|
|
|
